Company Filing History:
Years Active: 2010
Title: Innovations in Pharmaceutical Chemistry by Swapnil Shreekant Kore
Introduction
Swapnil Shreekant Kore is a notable inventor based in Mumbai, India, recognized for his contributions to the field of pharmaceutical chemistry. With a focus on innovative processes, Swapnil has developed significant methodologies that enhance the production of key pharmaceutical compounds.
Latest Patents
Swapnil holds a patent for a novel process for the preparation of atovaquone and its intermediates. This invention elucidates a unique method where 1,4-naphthoquinone is reacted with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid, followed by halogenation to yield a dihalo-compound. The process proceeds through dehydrohalogenation of the dihalo-compound, resulting in a monohalogeno-compound, which undergoes hydrolysis to yield atovaquone. Notably, the invention presents atovaquone in a substantially pure and well-defined polymorphic form, designated as 'Form IPCA-ATO,' along with its preparation method.
Career Highlights
Swapnil is associated with Ipca Laboratories Limited, a prominent player in the pharmaceutical sector. His expertise in synthesizing complex compounds plays a pivotal role in advancing the company's research and development capabilities. With one patent to his name, his innovative spirit exemplifies the fusion of creativity and science within the pharmaceutical industry.
Collaborations
Throughout his career, Swapnil has collaborated with esteemed colleagues such as Ashok Kumar and Suneel Yeshwant Dike. These collaborations have fostered a dynamic work environment at Ipca Laboratories Limited, where the sharing of ideas and expertise accelerates the development of groundbreaking pharmaceutical solutions.
Conclusion
In conclusion, Swapnil Shreekant Kore stands out as an influential inventor in the realm of pharmaceutical innovations. His contributions, particularly the patent for the preparation of atovaquone, highlight his commitment to advancing medical science. As he continues to work alongside colleagues at Ipca Laboratories Limited, his future endeavors promise to impact the industry positively, contributing to the development of effective treatments and enhancing healthcare outcomes.